Saturday Aug 23
With Cyclacel, The Waiting Is The Hardest Part
Cyclacel shares have weakened as investors have avoided riskier biotechs, and perhaps due to some worries about potential competitive drugs sponsored by larger companies in pharma/biotech.
Celator Pharmaceuticals, Inc. Initiates Pharmacokinetic And...
Celator Pharmaceuticals, Inc. , a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the first patient has been enrolled in a Phase 2 pharmacokinetic and pharmacodynamics study evaluating the effects of CPX-351 Liposome Injection on cardiac repolarization in adult patients with acute hematologic ... (more)
Synta Reports Second Quarter Financial Results and Provides Corporate Update
"Since the beginning of this year, ganetespib has reached several important clinical milestones across studies and cancer types, including encouraging results from the GALAXY-1 and ENCHANT Phase 2 studies in lung and breast cancer, and graduation to the Phase 3 extension in the AML LI-1 trial," said .
New Nanoparticles Findings from University of Texas Described [Just...
However, acquired tumor cell resistance often limits its use." The news correspondents obtained a quote from the research from the , "Previously, we discovered that 4- -stearoyl gemcitabine solid lipid nanoparticles -GemC18-SLNs) can overcome multiple acquired gemcitabine resistance mechanisms, including RRM1 overexpression.